Roth Nadina, Rösch Christiane Sophie, Krause Axel, Kalteis Manfred, Enkner Wolfgang, Haller Maria, Cejka Daniel, Függer Reinhold, Biebl Matthias
Surgical Department for General, Visceral, Thoracic, Transplantation and Vascular Surgery, Ordensklinikum Linz Elisabethinen, Linz, Austria.
Specialist for General, Visceral and Thoracic Surgery, Department of General, Visceral, Transplantation, Thoracic and Vascular Surgery, Ordensklinikum Elisabethinen, Fadingerstr. 2, 4020 Linz, Austria.
Eur Surg. 2023;55(1):31-35. doi: 10.1007/s10353-022-00781-9. Epub 2022 Oct 14.
Due to immunosuppressive therapy, transplant patients are more susceptible to viral and bacterial infections. A potentially deadly new virus haunted us in 2020: SARS-CoV‑2, causing coronavirus disease 19 (COVID-19). We analyzed the consequences of this previously unknown risk for our living-donor transplant program in the first year of the pandemic. After the complete lockdown in spring 2020, our transplant center in Linz resumed the living-donor kidney transplantation program from June to September 2020, between the first and second waves of COVID-19 in Austria. We compared the outcomes of these living-donor kidney transplantations with the transplant outcomes of the corresponding periods of the three previous years. From June 4 to September 9, 2020, five living-donor kidney transplantations were performed. All donors and recipients were screened for COVID 19 infection by PCR testing the day before surgery. Kidney transplant recipients remained isolated in single rooms until discharge from hospital. All recipients and donors remained SARS-CoV‑2 negative during the follow-up of 10 months and have been fully vaccinated to date. The number of living transplants in the studied period of 2020 was constant compared to the same months of 2017, 2018, and 2019. Living-donor kidney transplantation can be continued using testing for SARS-CoV‑2 and meticulous hygienic precautions in epidemiologically favorable phases of the SARS-CoV‑2 pandemic. Donors and recipients should be carefully selected and informed about risks and benefits.
由于免疫抑制治疗，移植患者更容易受到病毒和细菌感染。2020年，一种潜在致命的新型病毒困扰着我们：严重急性呼吸综合征冠状病毒2（SARS-CoV-2），引发了冠状病毒病19（COVID-19）。我们分析了在疫情的第一年，这种前所未知的风险对我们的活体供体移植项目产生的影响。在2020年春季全面封锁之后，我们位于林茨的移植中心于2020年6月至9月恢复了活体供体肾移植项目，当时奥地利正处于COVID-19的第一波和第二波疫情之间。我们将这些活体供体肾移植的结果与前三年同期的移植结果进行了比较。2020年6月4日至9月9日，进行了5例活体供体肾移植手术。所有供体和受体在手术前一天通过PCR检测进行了COVID-19感染筛查。肾移植受者一直单独隔离在单人病房，直到出院。在10个月的随访期间，所有受者和供体的SARS-CoV-2检测均为阴性，并且迄今为止都已完全接种了疫苗。与2017年、2018年和2019年的相同月份相比，2020年研究期间的活体移植数量保持稳定。在SARS-CoV-2大流行的流行病学有利阶段，通过对SARS-CoV-2进行检测并采取细致的卫生预防措施，可以继续进行活体供体肾移植。应该仔细挑选供体和受体，并告知他们相关风险和益处。
